The current standard of care for metastatic ER-positive/Her2 negative breast cancer utilizes the combination of either the estrogen receptor degrader Fulvestrant or aromatase inhibitors such as Letrozole with CDK4/6 inhibitors such as Palbociclib. Here, ERBB2 is linked to breast cancer.